R. Jones

INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)

M. Heinrich, S. George, J. Zalcberg, 2019, Annals of Oncology.

CLINICAL Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up † the ESMO Guidelines Committee and EURACAN*

E. Álava, A. Cesne, H. Joensuu, 2020 .